Introduction {#sec1}
============

Ubiquitin proteasome system (UPS) governs diverse cellular processes such as cell proliferation, cell cycle progression, transcription, and apoptosis through targetting specific substrate proteins for ubiquitylation and degradation. The ubiquitin-activating E1 enzyme, ubiquitin--conjugating E2 enzyme and ubiquitin-protein E3 ligase exert the multistep enzymatic processes to catalyze the ubiquitinated substrates. The SKP1--cullin1--F-box protein (SCF) E3 ligase complex, which is composed of the invariant components S-phase kinase-associated protein 1 (SKP1), the E3 ligase RBX1 (also known as ROC1) and cullin 1, as well as variable F-box proteins \[[@B1]\], is so far the best characterized E3 ligase family member \[[@B2]\]. The F-box proteins are able to bind to a distinct subset of substrates though its WD40 or leucine-rich domains and determine the substrate specificity of SCF complex \[[@B3]\]. Until now, 69 mammalian F-box proteins have been identified, they can be organized into three subclasses \[[@B4]\]: (i) the well-studied β-TRCP1, FBXW7 (also known as Fbw7, Sel-10, hCdc4, or hAgo), and β-TRCP2 (also known as FBXW11), which contain WD40 repeat domains; (ii) FBXL family members, including SKP2 (also known as FBXL1), which contain leucine-rich repeat domains; and (iii) FBXO proteins. Owing to the pivotal and indispensable roles in cell cycle regulation that have been identified, the relationship between these proteins and tumorigenesis attract much attention \[[@B5]\].

Breast cancer (BC) is the most common malignant disease that causes the most cancer-related deaths amongst females worldwide \[[@B6]\]. According to the expression patterns of hormone and growth factor receptors, BCs are classified into four major molecular subtypes: luminal A and B, HER2-like, and basal-like. Due to the heterogeneous and high morbidity of disease, the death rates of BC remain high \[[@B7]\]. Therefore, the detailed molecular mechanism underlying the BC development and progression is important to be explored, and it is essential to identify novel targets for predicting or treating BCs. Amongst the 69 F-box proteins, only four members---FBXW7, SKP2, β-TrCP1, and β-TrCP2---have been extensively studied, and 15 of them are so far identified to play determined roles in cancers and they are grouped into four categories: tumor suppressive, oncogenic, context-dependent, or undetermined functions in cancer \[[@B4]\]. Nevertheless, the prognostic values of each individual F-box proteins, specially at the mRNA level in BCs are still elusive.

Kaplan--Meier plotter (KM plotter) database is constructed based on the gene expression data and survival information downloaded from GEO (<http://www.ncbi.nlm.nih.gov/geo/>) \[[@B8]\]. Owing to its ease of access to database, this online survival analysis tool has been widely used to analyze the prognostic values of individual genes in lung cancer, ovarian cancer, gastric cancer, and BC \[[@B9]\]. In the present study, we selected 15 well-identified members of F-box family to assess their prognostic values for BC. The relationship between F-box mRNA expression and clinical characteristics were also analyzed by KM plotter database.

Materials and methods {#sec2}
=====================

An online KM plotter database \[[@B8]\] was used to assess the prognostic values of 15 F-box members' mRNA expression in BC as previously described \[[@B11]\]. The background database of this online survival analysis tool was established using gene expression data and survival information of 1809 patients (1402 BC patients with overall survival (OS) data) downloaded from GEO (Affymetrix HGU133A and HGU133+2 microarrays) \[[@B8]\]. These two microarrays are frequently used because these two arrays contain 22277 probe sets at nearly identical platforms. An overview of the clinical data is presented in [Table 1](#T1){ref-type="table"} \[[@B13]\]. Each of 15 individual members of F-box members were entered into this online analysis database respectively (<http://kmplot.com/analysis/index.php?p=service&cancer=breast>), and Kaplan--Meier survival curves were acquired. Hazard ratio (HR), 95% confidence intervals (CI), and log rank *P*-values were also obtained on the webpages, and *P-*values of \<0.05 were considered as statistically significant.

###### Clinical characteristics of the microarray datasets used in the analysis

  GEO ID     Platform   Number of patients   Age (years)   Tumor size (cm)   ER+   Lymph node+   Grade 1   Grade 2   Grade 3   Relapse event   Average relapase-free survival   References
  ---------- ---------- -------------------- ------------- ----------------- ----- ------------- --------- --------- --------- --------------- -------------------------------- -------------------------
  GSE12276   GPL570     204                  NA            NA                NA    NA            NA        NA        NA        204             2.2 ± 1.8                        Bos et al. (2009)
  GSE16391   GPL570     55                   61 ± 9        NA                55    33            2         35        18        55              3.0 ± 1.2                        Desmedt et al. (2009)
  GSE12093   GPL96      136                  NA            NA                136   0             NA        NA        NA        20              7.7 ± 3.2                        Zhang et al. (2009)
  GSE11121   GPL96      200                  NA            2.1 ± 1           NA    0             58        136       35        46              7.8 ± 4.2                        Schmidt et al. (2008)
  GSE9195    GPL570     77                   64 ± 9        2.4 ± 1           77    36            14        20        24        13              7.8 ± 2.5                        Loi et al. (2008)
  GSE7390    GPL96      198                  46 ± 7        2.2 ± 0.8         134   NA            30        83        83        91              9.3 ± 5.6                        Desmedt et al. (2007)
  GSE6532    GPL96      82                   64 ± 10       2.5 ± 1.2         70    22            0         54        1         19              6.1 ± 3.1                        Loi et al. (2007)
  GSE5327    GPL96      58                   NA            NA                0     NA            NA        NA        NA        11              6.8 ± 3.1                        Minn et al. (2007)
  GSE4922    GPL96      1                    69            2.2               1     0             1         0         0         0               12.17                            Ivshina et al. (2006)
  GSE2494    GPL96      251                  62 ± 14       2.2 ± 1.3         213   84            67        128       54        NA              NA                               Miller et al. (2005)
  GSE2990    GPL96      102                  58 ± 12       2.3 ± 1.1         73    15            27        20        36        40              6.6 ± 3.9                        Sotirious et al. (2006)
  GSE2034    GPL96      286                  NA            NA                209   0             NA        NA        NA        107             6.5 ± 3.5                        Wang et al. (2005)
  GSE1456    GPL96      159                  NA            NA                NA    NA            28        58        61        40              6.2 ± 2.3                        Pawitan et al. (2005)
  Total                 1809                 57 ± 13       2.2 ± 1.1         968   190           227       534       312       646             6.4 ± 4.1                        

Results {#sec3}
=======

Prognostic roles of F-box in all BC patients {#sec3-1}
--------------------------------------------

We first examined the prognostic effects of 15 members of *F-box* mRNA in all BC patients by KM plotter database. As shown in [Figure 1](#F1){ref-type="fig"}, FBXO1 (HR = 1.39 95%CI: 1.12--1.72, *P*=0.0025), FBXO31 (HR = 1.37 95%CI: 1.10--1.69, *P*=0.0040), SKP2 (HR = 1.85 95%CI: 1.49--2.30, *P*=0.0008), and FBXO5 (HR = 1.65 95%CI: 1.33--2.05, *P*=0.0004) were significantly associated with worse OS in all BC patients ([Figure 1](#F1){ref-type="fig"}A--D). However, FBXO4 (HR = 0.56 95%CI: 0.41--0.77, *P*=0.0003) and β-TrCP1 (HR = 0.73 95%CI: 0.59--0.90, *P*=0.0034) were associated with better prognosis ([Figure 1](#F1){ref-type="fig"}E,F). The mRNA expression levels of FBXW8, FBXL3, FBXO10, FBXO11, FBXO18, FBXO9, β-TrCP2, and FBXL10 were not correlated with OS in all BC patients (Supplementary Figure S1).

![The prognostic values of the mRNA expression of F-box in all BCs\
Overexpression of FBXO1 (**A**), FBXO31 (**B**), SKP2 (**C**), and FBXO5 (**D**) are significantly associated with worse OS in all BC patients. Overexpression of FBXO4 (**E**) and β-TrCP1 (**F**) are associated with better prognosis.](bsr-39-bsr20180949-g1){#F1}

Prognostic roles of F-box members in different BC subtypes {#sec3-2}
----------------------------------------------------------

Then, we respectively assessed the prognostic effects of F-box in BCs with different intrinsic subtypes. For luminal A type BC patients, FBXO1 (HR = 1.46 95%CI: 1.02--2.08, *P*=0.0358), SKP2 (HR = 1.80 95%CI: 1.25-2.57, *P*=0.0012), and FBXO5 (HR = 1.92 95%CI: 1.33--2.76, *P*=0.0004) were correlated to worse survival ([Figure 2](#F2){ref-type="fig"}A--C). Whereas FBXW8 (HR = 0.55 95%CI: 0.33--0.92, *P*=0.0219) and β-TrCP1 (HR = 0.56 95%CI: 0.39--0.80, *P*=0.0014) were significantly associated with longer OS ([Figure 2](#F2){ref-type="fig"}D,E). The rest members of F-box were not correlated to prognosis in luminal A type BC (Supplementary Figure S2).

![The prognostic values of the mRNA expression of F-box in luminal A type BCs\
The high expression of FBXO1 (**A**), SKP2 (**B**), and FBXO5 (**C**) are correlated to worse survival, and FBXW8 (**D**) and β-TrCP1 (**E**) are associated with longer OS in luminal A type BC patients.](bsr-39-bsr20180949-g2){#F2}

In luminal B type BC patients, only high mRNA expression of FBXO4 was significantly associated with better survival, the HR was 0.38 (95%CI: 0.18-0.79, *P*=0.0070, [Figure 3](#F3){ref-type="fig"}A). The remaining F-box members did not show any prognostic value in luminal B type BC patients (Supplementary Figure S3).

![The prognostic values of some selected F-box in luminal B type, HER2-expressing or Basal-like BCs\
Survival curves of FBXO4 (**A**) are plotted for luminal B type BC patients. Survival curves of FBXW8 (**B**) and FBXL3 (**C**) are plotted for HER2-overexpressing BC patients. Survival curves of FBXW8 (**D**) are plotted for basal-like BC patients.](bsr-39-bsr20180949-g3){#F3}

In HER2-overexpressing BC, high mRNA expression of FBXW8 was associated with poor prognosis, the HR was 2.29 (95%CI: 0.99, 5.30), *P*=0.0475 ([Figure 3](#F3){ref-type="fig"}B). However, FBXL3 (HR = 0.36, 95%CI: 0.16--0.84, *P*=0.0134) was significantly associated with better OS ([Figure 3](#F3){ref-type="fig"}C). The rest of F-box members were not associated with prognosis in HER2-overexpressing BC patients (Supplementary Figure S4).

With regard to basal-like BC, none of the selected F-box members was associated with prognosis (Supplementary Figure S5). Only FBXW8 (HR = 0.52, 95%CI: 0.27--1.01, *P*=0.051) was modestly associated with better prognosis ([Figure 3](#F3){ref-type="fig"}D).

Prognostic roles of F-box members in BC patients with different status of TP53 {#sec3-3}
------------------------------------------------------------------------------

Furthermore, we assessed prognostic values of F-box members in BCs with different status of TP53. As shown in [Table 2](#T2){ref-type="table"}, only SKP2 (HR = 1.79, 95%CI: 0.92--3.49, *P*=0.0809) was modestly associated with worse survival for wild-TP53-type BCs, the other F-box members were not correlated with prognosis. In mutant-TP53-type BC, FBXL3 was significantly associated with longer OS, however, the other F-box members did not show any prognostic values.

###### The association between the F-box members and the prognosis of BC with different p53 status

  F-box family   Affymetrix IDs   p53      HR     95%CI          *P*-value
  -------------- ---------------- -------- ------ -------------- -----------
  FBXW7          229419_at        Mutant   1.99   (0.50, 7.98)   0.3193
                                  Wild     /      /              /
  FBXO4          223493_at        Mutant   1.20   (0.32, 4.48)   0.7888
                                  Wild     /      /              1.88)/
  FBXW8          231883_at        Mutant   1.01   (0.26, 3.90)   0.9886
                                  Wild     /      /              /
  FBXL3          225132_at        Mutant   0.11   (0.01, 0.91)   0.0136
                                  Wild     1.28   (0.55, 3.01)   0.5648
  FBXO1          204826_at        Mutant   0.94   (0.44, 2.01)   0.8786
                                  Wild     0.87   (0.46, 1.66)   0.6758
  FBXO10         227222_at        Mutant   0.83   (0.22, 3.07)   0.7745
                                  Wild     /      /              /
  FBXO11         222119_s\_at     Mutant   0.83   (0.38, 1.82)   0.6423
                                  Wild     0.57   (0.29, 1.12)   0.1004
  FBXO18         224683_at        Mutant   0.50   (0.13, 2.02)   0.3248
                                  Wild     /      /              /
  FBXO31         219785_s\_at     Mutant   0.53   (0.24, 1.19)   0.1201
                                  Wild     0.98   (0.51, 1.86)   0.9411
  SKP2           203625_at        Mutant   0.70   (0.33, 1.52)   0.3681
                                  Wild     1.79   (0.92, 3.49)   0.0809
  FBXO5          218875_at        Mutant   1.02   (0.46, 2.27)   0.9562
                                  Wild     1.24   (0.92, 3.49)   0.0809
  FBXO9          238472_at        Mutant   1.93   (0.48, 7.73)   0.3471
                                  Wild     /      /              /
  β-TrCP1        216091_s\_at     Mutant   1.47   (0.63, 3.43)   0.3684
                                  Wild     1.01   (0.53, 1.92)   0.9799
  β-TrCP2        209455_at        Mutant   0.79   (0.37, 1.71)   0.5514
                                  Wild     1.52   (0.79, 2.92)   0.2037
  FBXL10         226215_s\_at     Mutant   1.43   (0.38, 5.41)   0.6004
                                  Wild     /      /              /

Prognostic roles of F-box members in BC patients with different pathological grades {#sec3-4}
-----------------------------------------------------------------------------------

Next, we assessed prognostic values of F-box members in different pathological grade BCs. We could see from the [Table 3](#T3){ref-type="table"} that none of the F-box members was found to be associated with prognosis in grade I BC patients. While in grade II BC, FBXW7 (HR = 0.27, 95%CI: 0.07--1.02, *P*=0.0383) was correlated with better OS, FBXO1 (HR = 2.10, 95%CI: 1.34--3.30, *P*=0.0001) and SKP2 (HR = 1.56, 95%CI: 1.01--2.40, *P*=0.0420) were significantly associated with poor survival. However, the higher mRNA expression of FBXO4 (HR = 0.59, 95%CI: 0.35-0.99, *P*=0.0430) and FXBL3 (HR = 0.52, 95%CI: 0.31--0.88, *P*=0.0136) were associated with better survival for grade III BCs.

###### Correlation of F-box with different pathological grade status of BC patients

  F-box family   Affymetrix IDs   Grades   HR     95%CI           *P-*value
  -------------- ---------------- -------- ------ --------------- -----------
  FBXW7          229419_at        I        0.57   (0.05, 6.27)    0.6390
                                  II       0.27   (0.07, 1.02)    0.0383\*
                                  III      1.32   (0.79, 2.21)    0.2833
  FBXO4          223493_at        I        1.66   (0.15, 18.35)   0.6780
                                  II       1.10   (0.35, 3.48)    0.8711
                                  III      0.59   (0.35, 0.99)    0.0430\*
  FBXW8          231883_at        I        0.26   (0.02, 3.57)    0.2910
                                  II       0.94   (0.30, 2.92)    0.9179
                                  III      0.79   (0.48, 1.32)    0.3707
  FBXL3          225132_at        I        2.02   (0.18, 22.59)   0.5610
                                  II       0.80   (0.25, 2.51)    0.6973
                                  III      0.52   (0.31, 0.88)    0.0136\*
  FBXO1          225132_at        I        0.73   (0.28, 1.87)    0.5070
                                  II       2.10   (1.34, 3.30)    0.0001\*
                                  III      0.91   (0.66, 1.27)    0.5884
  FBXO10         227222_at        I        0.44   (0.04, 4.86)    0.4900
                                  II       0.87   (0.28, 2.70)    0.8039
                                  III      1.58   (0.95, 2.64)    0.0768
  FBXO11         222119_s\_at     I        0.66   (0.26, 1.67)    0.3750
                                  II       0.89   (0.58, 1.38)    0.6109
                                  III      1.37   (0.98, 1.91)    0.0628
  FBXO18         224683_at        I        1.76   (0.16, 19.53)   0.6390
                                  II       0.59   (0.18, 1.97)    0.3872
                                  III      0.81   (0.49, 1.36)    0.4288
  FBXO31         219785_s\_at     I        1.11   (0.45, 2.76)    0.8187
                                  II       1.22   (0.79, 1.87)    0.3661
                                  III      1.32   (0.95, 1.83)    0.0953
  SKP2           203625_at        I        1.59   (0.65, 3.92)    0.3078
                                  II       1.56   (1.01, 2.40)    0.0420\*
                                  III      1.01   (0.73, 1.40)    0.9648
  FBXO5          218875_s\_at     I        1.65   (0.67, 4.07)    0.2727
                                  II       1.41   (0.92, 2.17)    0.1110
                                  III      1.38   (0.99, 1.91)    0.0570
  FBXO9          238472_at        I        0.57   (0.05, 6.27)    0.6390
                                  II       1.91   (0.58, 6.37)    0.2812
                                  III      0.98   (0.58, 1.65)    0.9426
  β-TrCP1        216091_s\_at     I        0.60   (0.24, 1.51)    0.2719
                                  II       1.01   (0.66, 1.55)    0.9678
                                  III      0.84   (0.60, 1.16)    0.2890
  β-TrCP2        209455_at        I        0.88   (0.35, 2.20)    0.7763
                                  II       1.04   (0.68, 1.59)    0.8656
                                  III      1.30   (0.94, 1.81)    0.1155
  FBXL10         226215_s\_at     I        0.50   (0.04, 5.54)    0.5610
                                  II       0.51   (0.15, 1.70)    0.2661
                                  III      0.66   (0.39, 1.11)    0.1146

Discussion {#sec4}
==========

F-box protein is one of the core components of SCF multisubunit E3 ligase complex, it determines the substrate specificity of SCF complex by binding to substrates through WD40 or leucine-rich domains \[[@B3]\]. F-box family members are divided into three subclasses, including 10 FBXW proteins, 22 FBXL proteins, and 37 FBXO proteins. F-box proteins are implicated in multiple cellular processes, including cell proliferation, apoptosis, angiogenesis, and invasion via mediating degradation of numerous substrates \[[@B4]\]. In this study, by using an online survival analysis tool, we found that high mRNA expression of FBXO4 and β-TrCP1 were associated with better outcome for BCs, and FBXO1, FBXO31, FBXO5, and SKP2 were significantly correlated to worse prognosis.

FBXO4 is generally identified as a tumor suppressor, FBXO4-deficient mice will develop highly aggressive melanomas, as well as lymphomas, histolytic sarcomas, mammary and hepatocellular carcinomas \[[@B26],[@B27]\]. Mutation or loss of FBXO4 impairs the dimerization of the SCF^Fbx4^ ligase, resulting in accumulation of nuclear cyclin D1 and oncogenic transformation \[[@B28]\]. However, how FBXO4 determinates the cell fates of BC cells is unclear. We searched the Pubmed database and did not find any articles on the relationship between FBXO4 and BC. Hence, we used the KM plotter database to analyze the prognostic effect of FBXO4 in BC and found that high mRNA expression of FBXO4 was associated with longer OS for all BC patients. Additionally, high *FBXO4* mRNA expression was correlated to better survival in luminal B and grade III BC patients.

β-TRCP1 and β-TRCP2 either exert their oncogenic or tumor suppressive roles depending on the specific cellular context(s). Interestingly, female mice with β-TRCP1^−/−^ mammary glands exhibited hypoplastic phenotypes, which suggested that β-TRCP1 was critical for tissue development \[[@B31]\]. β-TRCP1 was significantly up-regulated in prostate cancer and hepatoblastoma \[[@B32]\], and high expression of β-TRCP1 at both mRNA and protein levels in colorectal cancer were correlated with poor clinical prognosis \[[@B33]\]. However, in gastric cancers, somatic mutation of β-TRCP1, which impaired ligase activity, contributed to tumor development and progression through β-catenin stabilization \[[@B34]\]. In TNBC cells, knockdown of β-TRCP1 reduced the cell proliferative ability \[[@B35]\], implicating a tumor suppressive role of β-TRCP1 in BC. Here, we showed that high mRNA expression of β-TRCP1 was associated with longer OS in luminal A type BC or all BC patients. On the other hand, β-TRCP2 also has tumor type-dependent roles in dominating tumorigenesis. Overexpression of β-TRCP2 was observed in a variety of human cancers, including prostate, breast, and gastric cancers \[[@B36]\]. Whereas mutation of β-TRCP2 in gastric cancer caused β-catenin accumulation, and contributed to carcinogenesis by activating WNT signaling pathway \[[@B37]\]. Inhibition of β-TRCP2 by miR-106b-25 cluster in non-small lung cancer cells promoted cell invasion and metastasis \[[@B38]\]. However, β-TRCP2 was not associated with prognosis in BC patients according to the current results analyzed by KM plotter database.

FBXO1, also known as cyclin F, meditates centrosome duplication and is critical for maintaining genome integrity, thus it has been regarded as an emerging tumor suppresser \[[@B39]\]. Knockout FBXO1 in MEFs leads to cell cycle defects \[[@B40]\]. In hepatocellular carcinoma, FBXO1 was down-regulated and low expression levels of FBXO1 were significantly associated with worse clinical characteristics and poorer prognosis \[[@B41]\]. Unexpectedly, we suggested an uncanonical function of FBXO1 exerted in BC, as we showed that high mRNA expression levels of FBXO1 were associated with worse survival in BC patients.

FBXO31 was regarded as an emerging tumor suppressor, which is often down-regulated in several human cancers, including BC, gastric cancer, and hepatocellular cancer \[[@B42]\]. FBXO31 was involved in DNA damage response for maintaining genomic stability. After DNA damage induced by genotoxic agents or γ-irradiation, phosphorylation of FBXO31 was increased immediately \[[@B45]\], then SCF/FBXO31 promoted MDM2 ubiquitination, resulting in accumulation of p53 and growth arrest \[[@B46]\]. Overexpression of FBXO31 in cancer cells inhibited cell growth and colon formation, and ectopic expression of FBXO31 significantly decreased tumor formation in xenograft nude mice \[[@B42]\]. However, overexpression of FBXO31 in lung cancer promoted cell growth and metastasis \[[@B47]\], and higher expression levels of FBXO31 predicted worse survival in esophageal squamous cell carcinoma \[[@B48]\]. Therefore, FBXO31 may also exert its role in tumorigenesis depending on tumor cell types. In our study, we used the KM plotter database to reveal that higher expression of *FBXO31* mRNA was associated with poorer prognosis in BC patients.

The F-box protein SKP2 plays an oncogenic role in human cancers. Mechanistically, SKP2 facilitates ubiquitination and degradation of many tumor suppressors, such as p21, p27, p57, FOXO1, and others \[[@B2]\]. Furthermore, SKP2 enhances DNA damage response and promotes DNA double-strand break repair pathways in cancer cells \[[@B49]\]. As a result, SKP2 is up-regulated in several human cancers, including colorectal cancer \[[@B50]\], bladder cancer \[[@B51]\], BC \[[@B52],[@B53]\], melanoma \[[@B54]\], prostate cancer \[[@B55]\], hepatocellular cancer \[[@B56]\], cervical cancer \[[@B49]\], and lymphoma \[[@B57]\]. In BC, SKP2 has been reported to correlate to poorer prognosis \[[@B58]\]. Additionally, immunohistochemical analysis indicated that overexpression of SKP2 were more frequently observed in ER-negative BC \[[@B53],[@B59]\]. In our study, the higher expression of *SKP2* mRNA was significantly associated with shorter OS in luminal A type BC patients. Previous results have indicated that SKP2 expression was associated with higher tumor grade in BCs or bladder cancers \[[@B51],[@B59],[@B60]\]. Interestingly, we showed that high mRNA expression of SKP2 was correlated to poor prognosis in grade II BC patients, but not in grade I or grade III BC patients.

FBXO5 is also suggested to play an emerging oncogenic role in human cancers. FBXO5 functions as an endogenous inhibitor of APC/C, which results in the stabilization of APC/C ubiquitin substrates, such as cyclin A, cylcin B, or Secure \[[@B61]\]. Up-regulation of FBXO5 in p53-deficient cells could promote cell proliferation, tetraploidy, and genomic instability \[[@B62]\]. By analysis of more than 1600 benign and malignant tumors, Lehman et al. \[[@B61]\] suggested that FBXO5 was strongly overexpressed in malignant tumors, rather than in benign tumors. Furthermore, overexpression of FBXO5 was associated with poor outcome in ovarian cancer \[[@B63]\], prostate cancer \[[@B64]\], and hepatocellular carcinoma \[[@B65]\]. In BC patients, overexpression of FBXO5 was significantly correlated with histologic grade and prognosis \[[@B66]\]. Consistently, our results demonstrated that FBXO5 had an oncogenic role in BC, higher expression of FBXO5 in mRNA level was significantly associated with poorer survival, especially in luminal A type BC patients.

FBXO11 was able to inhibit tumor cell growth and induced cell death by target BCL-6 for degradation \[[@B67]\], and deletion or mutation of FBXO11 in pancreatic cancer patients was associated with poor prognosis \[[@B68]\]. In BCs, FBXO11 restrained tumor initiation and metastasis by promoting SNAIL ubiquitylation and degradation, and overexpression of FBXO11 was correlated with longer metastasis-free survival \[[@B69],[@B70]\]. However, our results did not find any relationship between the *FBXO11* mRNA expression and OS in BC.

FBXW8 forms a functional E3 ligase complex with cullin 7 to exert a tumor suppressive role \[[@B4]\]. Ectopic expression of FBXW8 in choriocarcinoma JEG-3 cells increased the percentage of cells at S-phase and decreased the percentage of G~2~/M-phase cells \[[@B71]\], suggesting that FBXW8 was critical for cell growth. As FBXW8-meditated cyclin D1 and HPK1 degradation was necessary for cancer cell growth \[[@B71],[@B72]\]. However, there is still no result about the prognostic role of FBXW8 in BC. Our results indicated that overexpression of *FBXW8* mRNA was significantly associated with better prognosis in luminal A and basal-like BC patients, however, it was correlated with worse survival in HER2-overexpressiong BC patients.

An accumulation of pathological data have been proved that FBXW7 is a tumor suppressor by targetting various oncogenic proteins, such as Notch, cyclin E, c-Myc, and c-Jun, for degradation \[[@B73],[@B74]\]. Interestingly, FBXW7 expressed in the host microenvironment also suppressed cancer metastasis depending on the FBXW7/NOTCH/CCL2 axis \[[@B75]\]. Hence, FBXW7 mutation, resulting in loss-of-function of FBXW7, was frequently observed amongst primary human cancers. Approximately 6% of human cancers were FBXW7 mutated, and 9% of primary endometrial cancers were FBXW7 mutated \[[@B76]\]. Reduced expression of FBXW7 has been reported to be correlated with worse outcomes in several human cancers, including gastric cancer \[[@B77]\], colorectal cancer \[[@B78]\], cervical squamous carcinoma \[[@B79]\], glioma \[[@B80]\], and prostate cancer \[[@B81]\]. For BCs, FBXW7 was significantly down-regulated, knockdown of FBXW7 in BC cells promoted cell proliferation, migration, and inhibited cell apoptosis \[[@B82],[@B83]\]. Inactivation of FBXW7 by promoter-specific methylation was correlated with poorly differentiated BC \[[@B84]\]. *FBXW7* mRNA expression was reduced in BC patients with high histological grade and hormone receptor-negative tumors \[[@B85]\]. A meta-analysis including 1900 patients indicated that the prognostic value of FBXW7 at mRNA level in BC was depending on ER status and molecular subtypes \[[@B86]\]. According to our results, increased mRNA expression of FBXW7 was associated with better OS only in grade II BC patients.

Amongst the large family members of F-box, only few members have been extensively studied. Here, we used the KM plotter database to assess the prognostic values of the selected 15 members of *F-box* mRNA expression in BC and demonstrated that FBXO1, FBXO31, SKP2, and FBXO5 were significantly associated with worse prognosis in BC patients. FBXO4 and β-TrCP1 were found to be correlated to better OS. These associated results provide new insights into F-box members in the development and progression of BC. Further studies are needed in order to get detailed understanding of functional characterization of each F-box member and determine whether they can be potential treatment targets of BC.
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APC/C

:   anaphase-promoting complex/cyclosome

β-TrCP1

:   β-transducin repeats containing proteins

BC

:   breast cancer

BCL-6

:   B-cell lymphoma 6 protein

CCL2

:   chemokine (C-C motif) ligand 2

CI

:   confidence interval

FBXO3

:   F-box only protein 3

GEO

:   gene expression omnibus

HPK1

:   hematopoietic progenitor kinase1

HR

:   hazard ratio

KM plotter

:   Kaplan--Meier plotter

MEF

:   mouse embryonic fibroblast

OS

:   overall survival

SCFise

:   SKP1--cullin1--F-box protein

SKP1

:   S-phase kinase-associated protein 1

TNBC

:   triple-negative breast cancer

WNT

:   wingless/integrated
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